PH12021550601A1 - Tlr8 agonist - Google Patents

Tlr8 agonist

Info

Publication number
PH12021550601A1
PH12021550601A1 PH12021550601A PH12021550601A PH12021550601A1 PH 12021550601 A1 PH12021550601 A1 PH 12021550601A1 PH 12021550601 A PH12021550601 A PH 12021550601A PH 12021550601 A PH12021550601 A PH 12021550601A PH 12021550601 A1 PH12021550601 A1 PH 12021550601A1
Authority
PH
Philippines
Prior art keywords
tlr8 agonist
tlr8
agonist
toll
isomer
Prior art date
Application number
PH12021550601A
Other languages
English (en)
Inventor
Zhe Cai
Fei Sun
Charles Z Ding
Shuhui Chen
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of PH12021550601A1 publication Critical patent/PH12021550601A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PH12021550601A 2018-09-19 2021-03-17 Tlr8 agonist PH12021550601A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811094969 2018-09-19
PCT/CN2019/106687 WO2020057604A1 (zh) 2018-09-19 2019-09-19 Tlr8激动剂

Publications (1)

Publication Number Publication Date
PH12021550601A1 true PH12021550601A1 (en) 2021-11-29

Family

ID=69888288

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12021550601A PH12021550601A1 (en) 2018-09-19 2021-03-17 Tlr8 agonist

Country Status (11)

Country Link
US (1) US12054482B2 (https=)
EP (1) EP3854794B1 (https=)
JP (1) JP7498702B2 (https=)
KR (1) KR102856089B1 (https=)
CN (2) CN112805283B (https=)
AU (1) AU2019344868B2 (https=)
CA (1) CA3112953A1 (https=)
ES (1) ES2999323T3 (https=)
PH (1) PH12021550601A1 (https=)
SG (1) SG11202102641RA (https=)
WO (1) WO2020057604A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202102641RA (en) 2018-09-19 2021-04-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Tlr8 agonist
EP4122931B1 (en) * 2020-03-18 2025-07-02 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystalline form of tlr8 agonist
CN116472047B (zh) * 2021-11-05 2025-06-17 中国医药研究开发中心有限公司 芳胺类衍生物及其制备方法和医药用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0503506D0 (en) 2005-02-21 2005-03-30 4 Aza Bioscience Nv Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
PT2268618E (pt) 2008-03-03 2015-10-12 Novartis Ag Compostos e composições moduladores da actividade tlr
SG194852A1 (en) 2011-05-18 2013-12-30 Janssen R & D Ireland Quinazoline derivatives for the treatment of viral infections and further diseases
WO2013022766A1 (en) 2011-08-05 2013-02-14 Flynn Gary A Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
EP2925729B1 (en) 2012-11-16 2017-10-18 Janssen Sciences Ireland UC Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
WO2016141092A1 (en) 2015-03-04 2016-09-09 Gilead Sciences, Inc. Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
EP3507288B1 (en) 2016-09-02 2020-08-26 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
CN109923106B (zh) 2016-09-02 2022-09-13 吉利德科学公司 toll样受体调节剂化合物
SG11202102641RA (en) 2018-09-19 2021-04-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Tlr8 agonist

Also Published As

Publication number Publication date
JP7498702B2 (ja) 2024-06-12
EP3854794A1 (en) 2021-07-28
JP2022501350A (ja) 2022-01-06
AU2019344868A1 (en) 2021-04-15
AU2019344868B2 (en) 2024-06-27
ES2999323T3 (en) 2025-02-25
US12054482B2 (en) 2024-08-06
CN112805283A (zh) 2021-05-14
WO2020057604A1 (zh) 2020-03-26
SG11202102641RA (en) 2021-04-29
KR102856089B1 (ko) 2025-09-04
CN115650979A (zh) 2023-01-31
KR20210060567A (ko) 2021-05-26
CA3112953A1 (en) 2020-03-26
US20210371414A1 (en) 2021-12-02
EP3854794A4 (en) 2022-06-15
CN112805283B (zh) 2022-09-20
EP3854794B1 (en) 2024-11-27

Similar Documents

Publication Publication Date Title
ZA202206923B (en) New methylquinazolinone derivatives
EP4349840A3 (en) Pyrazolopyridine derivative having glp-1 receptor agonist effect
PH12020500673A1 (en) Compounds
NZ766978A (en) Atr inhibitor and application thereof
MX2021006181A (es) Una capsula de bebida.
NZ763551A (en) Compounds useful for inhibiting cdk7
AU2018271990A1 (en) Covalent inhibitors of KRAS
AU2018258581A8 (en) RAF-degrading conjugate compounds
SA520411524B1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
EP4501323A3 (en) Amino pyrimidine ssao inhibitors
EP4696377A3 (en) 5ht agonists for treating disorders
PH12021550601A1 (en) Tlr8 agonist
ZA201708234B (en) Delivery systems for controlled drug release
ZA202109175B (en) Novel peptide compound or pharmaceutically acceptable salt thereof
ZA202007737B (en) Pentacyclic compound
MX2020001615A (es) Compuestos de piridina sustituidos con azol.
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
AU2016351424A8 (en) Pyranodipyridine compound
PH12019550154A1 (en) Azetidine derivative
PH12020550649A1 (en) Anti-hbv tetrahydroisoxazolo[4,3-c]pyridine compounds
ZA202205170B (en) Process and intermediate for the preparation of oxetan-2-ylmethanamine
MX2020008689A (es) Composicion herbicida que comprende por lo menos un compuesto activo fenolico.
MX2016013439A (es) Formas solidas de un compuesto farmaceuticamente activo.
MX2020011247A (es) Formulaciones de liberacion sostenida para el suministro local de inhibidores de la cinasa 9 dependiente de ciclina (cdk9).
SA119400353B1 (ar) مشتق بيرازول مستبدل